fashion -WSS

fashion

author：explore 2025-10-01 00:17:26 - browse：47

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Diagnostic tests are hitting their mathematical limits

WSS

The painfully weak evidence on taking collagen to treat arthritis

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Wegovy cuts risk of cardiovascular events by 20%, study finds

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

CDC launches VaccineFinder tool to locate Covid

Flagship Pioneering launches a new biotech in two countries

focus

fashion

focus

At least 13 dead in Texas as scorching temps continue

As biotech industry slumps, bioscience job market is upside down

Heart attack and stroke risk calculators need revising

With clinical trial data readouts, here's how to spot spin

Jerome Adams on the need for new antivirals for Covid

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Hepatitis C has a cure — but many Americans still lack access to it

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Cancer drug shortages should be causing more outrage

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

focus

What don’t we know about an Alzheimer’s drug side effect?

‘The Bear’ and hospitality in hospitals

FTX founder Sam Bankman

Sage's campaign to raise awareness of postpartum depression hits a nerve

CDC launches VaccineFinder tool to locate Covid

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Wikipedia

focus

leisure time

Wikipedia